Compare BioNTech SE - ADR (BNTX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Williams-Sonoma, Inc. — how do they compare? BioNTech SE - ADR trades at $90.88 (market cap $22.86B), while Williams-Sonoma, Inc. trades at $222.59 (market cap $25.51B). The key difference: BioNTech SE - ADR and Williams-Sonoma, Inc. are close in size by market cap, and Williams-Sonoma, Inc. pays a 1.4% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WSM | |
|---|---|---|
Market Cap | $22.86B | $25.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $240.06 |
52-Week Low | $83.89 | $163.62 |
Enterprise Value | $6.53B | $26.35B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Williams-Sonoma (WSM) trades at $216.65, down 2.3% on the day, with a bullish technical outlook supported by moving averages but mixed oscillators. The company demonstrates strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has declined slightly from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten estimates, and the company maintains active brand collaborations and dividend payments.
The stock presents a balanced outlook with solid fundamentals and analyst consensus near the current price, but faces risks from revenue volatility and competitive pressures. Upside potential exists if earnings momentum continues, while macroeconomic headwinds and retail sector challenges pose downside risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
